Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Second allografts for relapsed hematologic malignancies: feasibility of using a different donor

Bone Marrow Transplantation volume 35, pages 261–264 (2005)Cite this article

Summary:

A second allogeneic hematopoietic stem cell transplant (HSCT) for relapsed hematologic malignancies is an option in select patients after an initial allograft has failed. If the original donor is not available, a different donor may have to be considered. We report our experience of performing a second allogeneic HSCT using a different donor in patients with relapsed leukemia and lymphoma. In a 5-year period, six patients underwent a second allograft with myeloablative conditioning using a different donor. Four of these were retransplanted using a matched-unrelated donor. Four of the patients (67%) remain progression-free at a median follow-up of 32 months (range 3–72). There were no cases of transplant-related mortality. We conclude that a second allogeneic HSCT using a different donor is a viable option for selected patients relapsing after an allograft if the original donor is not available.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Kumar L . Leukemia: management of relapse after allogeneic bone marrow transplantation. J Clin Oncol 1994; 12: 1710–1717.

    Article  CAS  Google Scholar 

  2. Collins RH, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433–444.

    Article  Google Scholar 

  3. Mortimer J, Blinder MA, Schulman S et al. Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. J Clin Oncol 1989; 7: 50–57.

    Article  CAS  Google Scholar 

  4. Bosi A, Laszlo D, Labopin M et al. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2001; 19: 3675–3684.

    Article  CAS  Google Scholar 

  5. Michallet M, Tanguy M, Socié G et al. Second allogeneic haemotopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Société Française de Greffe de Moelle. Br J Haematol 2000; 108: 400–407.

    Article  CAS  Google Scholar 

  6. Kishi K, Takahashi S, Gondo H et al. Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes. Bone Marrow Transplant 1997; 19: 461–466.

    Article  CAS  Google Scholar 

  7. Chiang KY, Weisdorf DJ, Davies SM et al. Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant relapse. Bone Marrow Transplant 1996; 17: 39–42.

    CAS  Google Scholar 

  8. Russell JA, Bowen T, Brown C et al. Second allogeneic transplants for leukemia using blood instead of bone marrow as a source of hemopoietic cells. Bone Marrow Transplant 1996; 18: 501–505.

    CAS  Google Scholar 

  9. Radich JP, Sanders JE, Buckner CD et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol 1993; 11: 304–313.

    Article  CAS  Google Scholar 

  10. Mrsic M, Horowitz MM, Atkinson K et al. Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant 1992; 9: 269–275.

    CAS  Google Scholar 

  11. Wagner JE, Vogelsang GB, Zehnbauer BA et al. Relapse of leukemia after bone marrow transplantation: effect of second myeloablative therapy. Bone Marrow Transplant 1992; 9: 205–209.

    CAS  Google Scholar 

  12. Spinolo JA, Yau JC, Dicke KA et al. Second bone marrow transplants for relapsed leukemia. Cancer 1992; 69: 405–409.

    Article  CAS  Google Scholar 

  13. Barrett CJ, Locatelli F, Treleaven JG et al. Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. Br J Haematol 1991; 79: 567–574.

    Article  CAS  Google Scholar 

  14. Champlin RE, Ho WG, Lenarsky C et al. Successful second bone marrow transplants for treatment of acute myelogenous leukemia or acute lymphoblastic leukemia. Transplant Proc 1985; 17: 496–499.

    Google Scholar 

  15. Frassoni F, Barrett AJ, Grañena A et al. Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the EBMT of 117 cases. Br J Haematol 1988; 70: 317–320.

    Article  CAS  Google Scholar 

  16. Mehta J, Powles R, Treleaven J et al. Outcome of acute leukemia relapsing after bone marrow transplantation: utility of second transplants and adoptive immunotherapy. Bone Marrow Transplant 1997; 19: 709–719.

    Article  CAS  Google Scholar 

  17. Gale RP, Bortin MM, van Bekkum DW et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987; 108: 400–407.

    Google Scholar 

  18. Atkinson K, Horowitz MM, Gale RP et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990; 75: 2459–2464.

    CAS  Google Scholar 

  19. Shilling HG, McQueen KL, Cheng NW et al. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood 2003; 101: 3730–3740.

    Article  CAS  Google Scholar 

  20. Falkenburg JH, van de Corput L, Marijt EW, Willemze R . Minor histocompatibility antigens in human stem cell transplantation. Exp Hematol 2003; 31: 743–751.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bone Marrow Transplant Program, Department of Internal Medicine, Loyola University Medical Center, Stritch School of Medicine, Maywood, IL, USA

    J E Duus, P J Stiff, J Choi, M Parthasarathy, T Rodriguez & A A Toor

Authors
  1. J E Duus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P J Stiff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Parthasarathy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Rodriguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A A Toor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A A Toor.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Duus, J., Stiff, P., Choi, J. et al. Second allografts for relapsed hematologic malignancies: feasibility of using a different donor. Bone Marrow Transplant 35, 261–264 (2005). https://doi.org/10.1038/sj.bmt.1704761

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704761

Keywords

This article is cited by

Search

Advanced search

Quick links